Lisinopril: Difference between revisions
Line 59: | Line 59: | ||
Lisinopril causes the kidneys to retain potassium, which may lead to [[hyperkalemia]]. |
Lisinopril causes the kidneys to retain potassium, which may lead to [[hyperkalemia]]. |
||
A severe allergic reaction can occur that rarely can |
A severe allergic reaction can occur that rarely can affect the bowel wall and secondarily cause abdominal pain. This "anaphylactic" reaction is very rare as well though must be given immediate medical attention. |
||
== History/brand names == |
== History/brand names == |
Revision as of 04:19, 14 February 2009
{{drugbox | IUPAC_name = N2-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline |synonyms = (2S)-1-[(2S)-6-amino-2-{[(1S)-1-carboxy-3-phenylpropyl]amino}hexanoyl]pyrrolidine-2-carboxylic acid | image = Lisinopril.svg | CAS_number = 83915-83-7 | ChemSpiderID = 4514933 | ATC_prefix = C09 | ATC_suffix = AA03 | ATC_supplemental = | PubChem = 5362119 | DrugBank = APRD00560 | C=21 | H=31 | N=3 | O=5 | molecular_weight = 405.488 g/mol | smiles = NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O | bioavailability = approx. 25%, but wide range between individuals (6 to 60%) | protein_bound = 0 | metabolism = None | elimination_half-life = 12 hours | excretion = Eliminated unchanged in Urine | pregnancy_category = D - teratogenic | legal_status = Rx-only | routes_of_administration = PO }} Lisinopril (lye-SIN-o-pril) is a drug of the angiotensin converting enzyme (ACE) inhibitor class that is primarily used in treatment of hypertension, congestive heart failure, heart attacks and also in preventing renal and retinal complications of diabetes. It has been compared with omapatrilat which is of similar function.
Historically, lisinopril was the third ACE inhibitor, after captopril and enalapril, and was introduced into therapy in the early 1990s.[1] Lisinopril has a number of properties that distinguish it from other ACE inhibitors: it is hydrophilic, has long half-life and tissue penetration and is not metabolized by the liver.
Pharmacology
Lisinopril is the lysine-analog of enalapril. Unlike other ACE inhibitors, lisinopril is not a prodrug and is excreted unchanged in the urine. In cases of overdosage, it can be removed from circulation by dialysis.
Clinical use
Its indications, contraindications and side effects are as those for all ACE inhibitors. Its long half-life allows for once a day dosing which aids patient compliance. The usual daily dose in all indications ranges from 2.5 mg in sensitive patients to 40 mg. Some patients have been treated with 80 mg daily and have tolerated this high dose well. Lower dosages must be used in patients with higher grade renal impairment (glomerular filtration rate (GFR) lower than 30 ml/min).
Adverse effects
Serious side effects that would require immediate medical attention include:
- chills, infection
- dark urine, decreased urination (oliguria)
- difficulty swallowing or breathing (signs of angioedema), allergic reaction (anaphylaxis)
- hoarseness
- itching
- rapid weight gain, stomach pain
- yellowing of skin or eyes (jaundice)
- abdominal pain, bloating, vomiting
- chest pain or tightness, dizziness, lightheadedness, fainting (syncope)
- dry cough
- fever
- joint pain
- rash
- diarrhea, loss of taste, nausea
- drowsiness, headache, tiredness
- Change in mood/ irrational behaviour
- blurred vision
- muscle cramps
- Fainting / Blackouts
Lisinopril causes the kidneys to retain potassium, which may lead to hyperkalemia.
A severe allergic reaction can occur that rarely can affect the bowel wall and secondarily cause abdominal pain. This "anaphylactic" reaction is very rare as well though must be given immediate medical attention.
History/brand names
Lisinopril was developed by Merck & Co. and is marketed worldwide as Prinivil or Tensopril and by AstraZeneca as Zestril. In India it is marketed by Micro Labs as Hipril. In the United States, a generic version is available. Like other ACE inhibitors, it is derived from the venom of the jararaca, a Brazilian pit viper (Bothrops jararaca).
References
- Bussien JP, Waeber B, Nussberger J, Gomez HJ, Brunner HR. Once-daily lisinopril in hypertensive patients: Effect on blood pressure and the renin-angiotensin system. Curr Therap Res 1985;37:342-51.
- Lisinopril info - rx-list.com
- Goodman & Gilman's : The pharmacological basis of therapeutics, 10th. ed., 2001
- Lisinopril.com - Lisinopril information
Footnotes
- ^ Patchett A, Harris E, Tristram E, Wyvratt M, Wu M, Taub D, Peterson E, Ikeler T, ten Broeke J, Payne L, Ondeyka D, Thorsett E, Greenlee W, Lohr N, Hoffsommer R, Joshua H, Ruyle W, Rothrock J, Aster S, Maycock A, Robinson F, Hirschmann R, Sweet C, Ulm E, Gross D, Vassil T, Stone C (1980). "A new class of angiotensin-converting enzyme inhibitors". Nature. 288 (5788): 280–3. doi:10.1038/288280a0. PMID 6253826.
{{cite journal}}
: CS1 maint: multiple names: authors list (link)